XTL BIOPHARMACEUTICALS LTD (XTLB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 200K 400K 600K FY24: 451K FY24

Gross Profit Annual

0 1.5K 3K 4.5K FY24: 3K FY24

Operating Income Annual

-2.4M -1.6M -800K 0 800K 1.6M 2.4M FY20: -948K FY21: -1M FY22: -880K FY23: -765K FY24: -2.2M FY20 FY21 FY22 FY23 FY24

Net Income Annual

-3M -1.5M 0 1.5M 3M 4.5M FY20: -3M FY21: 435K FY22: -1.3M FY23: -1.8M FY24: -1M FY20 FY21 FY22 FY23 FY24

Cost of Revenue Annual

0 200K 400K 600K FY24: 448K FY24

Operating Cash Flow Annual

-1.8M -1.2M -600K 0 600K 1.2M 1.8M FY20: -850K FY21: -1M FY22: -901K FY23: -707K FY24: -1.6M FY20 FY21 FY22 FY23 FY24

Free Cash Flow Annual

-2.1M -1.4M -700K 0 700K 1.4M 2.1M FY15: -1.9M FY16: -1.7M FY19: -910K FY20: -851K FY24: -1.7M FY15 FY16 FY19 FY20 FY24

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 250M 500M 750M FY20: 514.2M FY21: 615.5M FY22: 544.9M FY23: 544.9M FY24: 704.2M FY20 FY21 FY22 FY23 FY24

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.